Home - Australian Pharmacist

The new normal

Graem Sims - September 18, 2019

Industry

A new PSA report describes the digital future of Australian health care, a ‘new normal’ with pharmacists front and centre, equipped with more information...

Indirect impacts of COVID-19

Chloe Hava - April 7, 2021

Industry

Australia has had relative success in suppressing the COVID-19 virus, but there continues to be myriad ongoing and wide ranging indirect impacts.

Choosing Wisely: new medicines advice service arrives

Ruth Cooper - December 19, 2018

Industry

The Pharmaceutical Society of Australia (PSA) has released a list of recommendations for healthcare professionals to ensure the safe use of medicines. The launch of...

My Health Record – where to from here?

Thea Cowie and David Barbeler - February 26, 2019

Industry

While the My Health Record (MHR) opt-out date of January 31 has come and gone, people still have the option to permanently delete their...

PSA’s critical role in 7CPA in spotlight

James Chalmers - July 26, 2019

Industry

Federal Health Minister Greg Hunt has asserted the critical role that PSA will play in drafting the 7th Community Pharmacy Agreement (CPA), shaping the...

Bringing pharmacists into the digital future

Ruth Cooper - July 28, 2019

Industry

PSA has unveiled a new digital health report, Connecting the dots: Digitally empowered pharmacists, at the PSA19 conference. The report, funded by the Australian Digital...

1...279280281...318 Page 280 of 318

ACT³	No comparable criteria
NSW⁴	· pharmacist gives the person an opportunity to seek advice as to the use of the substance · quantity, or for a purpose must accord with the recognised therapeutic standard of what is appropriate in the circumstances
NT⁵	· pharmacist must not intentionally supply to a person in a manner reckless to their circumstance
QLD⁶	· pharmacist reasonably believes the patient has a therapeutic need
SA	No comparable criteria
TAS⁷	· pharmacist forms the opinion use in the treatment of the patient is justified on consideration of the condition, disease or symptoms of the person
VIC⁸	· for treatment of a patient under pharmacist’s care · pharmacist has taken all reasonable steps to ensure a therapeutic need exists
WA⁹	No comparable criteria

ACT³	No comparable criteria
NSW⁴	· pharmacist gives the person an opportunity to seek advice as to the use of the substance · quantity, or for a purpose must accord with the recognised therapeutic standard of what is appropriate in the circumstances
NT⁵	· pharmacist must not intentionally supply to a person in a manner reckless to their circumstance
QLD⁶	· pharmacist reasonably believes the patient has a therapeutic need
SA	No comparable criteria
TAS⁷	· pharmacist forms the opinion use in the treatment of the patient is justified on consideration of the condition, disease or symptoms of the person
VIC⁸	· for treatment of a patient under pharmacist’s care · pharmacist has taken all reasonable steps to ensure a therapeutic need exists
WA⁹	No comparable criteria

ACT³	No comparable criteria
NSW⁴	· pharmacist gives the person an opportunity to seek advice as to the use of the substance · quantity, or for a purpose must accord with the recognised therapeutic standard of what is appropriate in the circumstances
NT⁵	· pharmacist must not intentionally supply to a person in a manner reckless to their circumstance
QLD⁶	· pharmacist reasonably believes the patient has a therapeutic need
SA	No comparable criteria
TAS⁷	· pharmacist forms the opinion use in the treatment of the patient is justified on consideration of the condition, disease or symptoms of the person
VIC⁸	· for treatment of a patient under pharmacist’s care · pharmacist has taken all reasonable steps to ensure a therapeutic need exists
WA⁹	No comparable criteria

ACT³	No comparable criteria
NSW⁴	· pharmacist gives the person an opportunity to seek advice as to the use of the substance · quantity, or for a purpose must accord with the recognised therapeutic standard of what is appropriate in the circumstances
NT⁵	· pharmacist must not intentionally supply to a person in a manner reckless to their circumstance
QLD⁶	· pharmacist reasonably believes the patient has a therapeutic need
SA	No comparable criteria
TAS⁷	· pharmacist forms the opinion use in the treatment of the patient is justified on consideration of the condition, disease or symptoms of the person
VIC⁸	· for treatment of a patient under pharmacist’s care · pharmacist has taken all reasonable steps to ensure a therapeutic need exists
WA⁹	No comparable criteria

Case scenario

Learning objectives

Introduction

Epidemiology

Aetiology and pathophysiology

Risk factors

Clinical features

Management

Knowledge to practice

Case scenario continued

Key points

References

Our author

Our reviewer

1. Therapeutic Guidelines overhaul UTI treatment

2. Is Rikodeine still being rescheduled?

What else was popular?

1. PBS co‑payment will drop

2. Transition to the new MMR credential must be completed

3. Continued freeze on PBS concessional co‑payment

4. Optional allowable discount phase out continues

5. New PSA standards for CPD accreditation launch

Is advance provision of S3s legal?

But don’t we need to assess a patient’s therapeutic need?

So when is advanced supply of S3 OK?

What other things do I need to consider?

So what about the Rikodeine?

Table 1 – Legal requirements for pharmacists when prescribing Schedule 3 medicines

References

Case scenario

Learning objectives

Introduction

Epidemiology

Aetiology and pathophysiology

Risk factors

Clinical features

Management

Knowledge to practice

Case scenario continued

Key points

References

Our author

Our reviewer

1. Therapeutic Guidelines overhaul UTI treatment

2. Is Rikodeine still being rescheduled?

What else was popular?

1. PBS co‑payment will drop

2. Transition to the new MMR credential must be completed

3. Continued freeze on PBS concessional co‑payment

4. Optional allowable discount phase out continues

5. New PSA standards for CPD accreditation launch

Is advance provision of S3s legal?

But don’t we need to assess a patient’s therapeutic need?

So when is advanced supply of S3 OK?

What other things do I need to consider?

So what about the Rikodeine?

Table 1 – Legal requirements for pharmacists when prescribing Schedule 3 medicines

References

Case scenario

Learning objectives

Introduction

Epidemiology

Aetiology and pathophysiology

Risk factors

Clinical features

Management

Knowledge to practice

Case scenario continued

Key points

References

Our author

Our reviewer

1. Therapeutic Guidelines overhaul UTI treatment

2. Is Rikodeine still being rescheduled?

What else was popular?

1. PBS co‑payment will drop

2. Transition to the new MMR credential must be completed

3. Continued freeze on PBS concessional co‑payment

4. Optional allowable discount phase out continues

5. New PSA standards for CPD accreditation launch